PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: Guest Blog
The 'S' Word in Healthcare Reform
by Tom Norton
In little more than two years, the main elements of the HCR will take hold across the nation. As implementation continues to ramp up, one of the more intriguing questions surrounding its activation is, is the “S” word being realized?…That is, “S” as in “savings.” Are the much publicized “savings” that were projected [...]
Also posted in Regulatory, Strategy, healthcare Tagged ACO, CLASS Act, healthcare costs, healthcare reform, HHS, Medicare Advantage 3 Comments
A Simple Plan (to Save US Pharma Manufacturing)
Fernando Muzzio and Mauricio Futran propose a plan to turn around pharmaceutical manufacturing in the US.
Pharmaceutical manufacturing in the US is in rapid decline. Higher regulatory standards for efficacy and safety, among other reasons, have led to a significant level of difficulty in replacing “blockbusters” developed in the 1980s and 1990s that are now coming [...]
The Real Way to Lean Success: Suck Out the IT Fat
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat, writes Bill Drummy.
Consider this: In 2011, IMS projects US Rx market growth to be 2.7 percent. The top 10 pharma companies account for 50 percent of the entire market’s revenue, but will deliver only 10 percent of the [...]
Accelerated Approvals Could Raise Risks for Patients
By Erik Greb.
FDA approved 35 innovative drugs in fiscal 2011, including treatments for hepatitis C, prostate cancer, Hodgkin’s lymphoma, and lupus. This number of approvals is among the highest in the past 10 years, and it reflects the agency’s efforts to hasten patients’ access to new drugs. In the past two years, the agency’s lower [...]
Also posted in Regulatory, Safety Tagged approvals, Avandia, Chantrix, fast-track, FDA Leave a comment
JP Morgan Healthcare Conference Marked by Uncertainty